Sep 09 2026
 Data From Takeda’s Narcolepsy Type 1 Studies Demonstrating Improved Symptoms

Posted at Sep 09 2026
h in News by

Just announced from Takeda: New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life

OSAKA, Japan and CAMBRIDGE, Massachusetts, September 9, 2026 – Takeda (TSE:4502/NYSE:TAK) announced that the New England Journal of Medicine published results from two Phase 3 studies evaluating oveporexton (ORZEYFUL), an oral orexin receptor 2 (OX2R) agonist, in people with narcolepsy type 1 (NT1).1 Oveporexton is the first and only medicine to treat the underlying cause of NT1.

Read the full release

Print page